Summarized by Masters of Longevity from Longevity Docs News.
In 8,322 patients over 4.7 years, pelacarsen sharply lowered Lp(a) but not events.
Key Takeaways
- Pelacarsen lowered Lp(a) by about 75% for nearly five years.
- Event rates were 12.3% with drug and 12.1% with placebo.
- This randomized secondary‑prevention trial was funded by Novartis.
